The landmark decision to rejection of patent to anti-cancer drug ‘Glivec’ by Indian Supreme Court has catalysed range of debates around importance of innovation in research and development. The patent plea by Novartis for beta crystalline for of imanitib (i.e. glivec) was considered as an attempt to extend period of market exclusivity by filing patent for minor modification of molecule for which US patent was already been granted on 1996. Novartis has firmly stated court’s ruling as a setback to patent protection for its years of research invested in development of more stable and bioavailable form of imanitib, and offended by this decision they have issued host of statements about not investing in drug discovery R&D in India, and have also raised doubt about launching new life saving drugs in markets.
Submit your manuscripts at http://www.scitechnol.com/submitmanuscript-clinical-experimental-oncology.php